LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

LLY

1,088.53

+1.81%↑

JNJ

223.67

-0.06%↓

ABBV

218.6

+1.58%↑

UNH

381.21

+1.28%↑

MRK

114.86

-1.37%↓

Home・Stock List・ADMA Biologics Inc

ADMA Biologics Inc

Open

SectorHealthcare

7.73 2.38

Buy Sell

Overview

Share price change

24h

Current

Min

7.45

Max

7.75

Key metrics
By Trading Economics
Income	-4.1M 45M
Sales	-25M 114M
P/E Sector Avg	11.735 49.888
EPS	0.17
Profit margin	39.59
Employees	640
EBITDA	-13M 52M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+198.29% upside

Dividends
By Dow Jones
Next Earnings	5 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-546M 1.8B
Previous open	5.35
Previous close	7.73

News Sentiment

By Acuity

79%

21%

301 / 344 Healthcare

ADMA Biologics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

2 Jun 2026, 20:30 UTC

Earnings

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 Jun 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 Jun 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 Jun 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 Jun 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 Jun 2026, 23:01 UTC

Acquisitions, Mergers, Takeovers

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 Jun 2026, 23:01 UTC

Acquisitions, Mergers, Takeovers

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 Jun 2026, 23:00 UTC

Acquisitions, Mergers, Takeovers

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 Jun 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 Jun 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 Jun 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 Jun 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 Jun 2026, 21:00 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 Jun 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2 Jun 2026, 20:46 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 Jun 2026, 20:38 UTC

Earnings

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 Jun 2026, 20:21 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 Jun 2026, 20:12 UTC

Earnings

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Product Rev $594M

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 Jun 2026, 20:05 UTC

Earnings

Palo Alto Networks 3Q Loss $177M >PANW

Peer Comparison

Price change

ADMA Biologics Inc Forecast

Price Target

By TipRanks

198.29% upside

12 Months Forecast

Average 22.67 USD 198.29%

High 30 USD

Low 18 USD

Based on 3 Wall Street analysts offering 12 month price targets forADMA Biologics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to ADMA Biologics Inc - Dist in the past 3 months.

Sentiment

By Acuity

301 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.